Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients.

[powerpress]

Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.

[powerpress]

Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.

[powerpress]